Showing 1 - 10 of 21
Persistent link: https://www.econbiz.de/10009515629
Persistent link: https://www.econbiz.de/10009864768
Objective: To estimate both the number of patients with hepatocellular carcinoma (HCC) eligible annually for second-line therapy following sorafenib in Germany and the healthcare costs accrued by patients meeting eligibility criteria. Methods: Patients with an HCC diagnosis and one or more...
Persistent link: https://www.econbiz.de/10012010774
Persistent link: https://www.econbiz.de/10008662728
Objective: To estimate both the number of patients with hepatocellular carcinoma (HCC) eligible annually for second-line therapy following sorafenib in Germany and the healthcare costs accrued by patients meeting eligibility criteria. Methods: Patients with an HCC diagnosis and one or more...
Persistent link: https://www.econbiz.de/10011896545
Persistent link: https://www.econbiz.de/10005167159
Persistent link: https://www.econbiz.de/10005167163
Persistent link: https://www.econbiz.de/10008674128
Persistent link: https://www.econbiz.de/10003644764
Persistent link: https://www.econbiz.de/10001210021